Understanding PCOS and the Role of Ultrasound in Diagnosis

Polycystic Ovary Syndrome (PCOS) is one of the most prevalent endocrine disorders among women of reproductive age, affecting 8% to 13% of this population worldwide. Despite its high incidence, PCOS remains a condition that is often misunderstood and misdiagnosed. A key diagnostic feature is the presence of polycystic ovarian morphology seen on ultrasound, but the link between the syndrome and these ovarian findings is more complex than it first appears. This article explores the relationship between PCOS and polycystic ovaries on ultrasound, the diagnostic criteria used by clinicians, and the implications for effective treatment and long-term health management.

What Are Polycystic Ovaries?

Polycystic ovaries are defined by the appearance of multiple small follicles in the ovaries, typically measuring between 2 mm and 9 mm in diameter. These follicles are actually immature egg sacs that have failed to grow and release an egg due to hormonal imbalances. On ultrasound, a polycystic ovary appears enlarged—often exceeding 10 cm³ in volume—with a string-of-pearls pattern of small follicles arranged along the periphery or scattered throughout the stroma. Importantly, the term "cyst" is somewhat misleading because these structures are not pathological cysts but rather arrested follicles. A healthy ovary in a normally cycling woman will show a few follicles at various stages, but in polycystic ovaries the number is significantly elevated. The current standard uses a threshold of 20 or more follicles per ovary when using newer high-frequency ultrasound transducers, though older criteria required 12 or more.

The presence of polycystic ovaries is not exclusive to PCOS. Up to 25% of women with regular ovulatory cycles and no other signs of hyperandrogenism may still show polycystic ovarian morphology on ultrasound. This is why ultrasound findings alone are insufficient for a diagnosis—they must be interpreted in the clinical context.

PCOS is a syndrome defined by a triad of features: hyperandrogenism (clinical or biochemical), ovulatory dysfunction (oligomenorrhea or anovulation), and polycystic ovarian morphology on ultrasound. According to the Rotterdam criteria, a woman must present with at least two of these three features to be diagnosed with PCOS. Thus, while polycystic ovaries are a cornerstone of diagnosis, a woman can have PCOS without ultrasound findings (if she has hyperandrogenism and ovulatory dysfunction), and conversely a woman can have polycystic ovaries without having PCOS.

Why the Distinction Matters

Missing this nuance can lead to either overdiagnosis or underdiagnosis of PCOS. For example, a woman with irregular periods and mild acne who has polycystic ovaries is likely to have PCOS and would benefit from management. On the other hand, a woman with regular cycles and no signs of androgen excess who happens to have polycystic ovaries on an incidental ultrasound does not meet the diagnostic threshold for PCOS and may not require medical intervention. This distinction is critical for both clinical decision-making and research.

Ultrasound in the Diagnosis of PCOS: Technical Considerations

Ultrasound imaging has become the gold standard for evaluating ovarian morphology. Transvaginal ultrasound is preferred over transabdominal because it provides higher resolution and better visualization of the ovarian stroma and follicle counts. The International PCOS Network recommends using a transducer frequency of 8 MHz or higher. The number of follicles per ovary is the primary criterion, but ovarian volume is also used—an ovary volume greater than 10 mL is considered abnormal. Recent guidelines have updated the follicle count threshold to ≥20 per ovary when using modern ultrasound equipment, though some centers still apply the older threshold of ≥12.

It is important to note that the ultrasound appearance can change over a woman's lifespan and with medical interventions such as oral contraceptives or metformin. The diagnostic window is also influenced by age; after menopause, the ovaries typically shrink and follicle counts decline, making the ultrasound criterion less useful.

Other Diagnostic Components: Clinical and Biochemical Hyperandrogenism

To complete the diagnostic picture, clinicians must assess for signs of hyperandrogenism. Clinical hyperandrogenism includes hirsutism (excess terminal hair in a male pattern), acne, and male-pattern alopecia. Biochemical hyperandrogenism is confirmed by elevated serum levels of total or free testosterone, androstenedione, or dehydroepiandrosterone sulfate (DHEA-S). However, standardized assays for free testosterone are not always reliable, and many laboratories use calculated free testosterone. Additionally, sex hormone-binding globulin (SHBG) levels are often low in PCOS, contributing to higher free androgen availability.

Ovulatory dysfunction is assessed by menstrual history. Women with PCOS typically experience infrequent periods (fewer than eight per year) or prolonged cycles longer than 35 days. Some may present with secondary amenorrhea. In women with regular cycles, ovulation can be confirmed with a mid-luteal progesterone level above 3 ng/mL.

Pathophysiology: Why Polycystic Ovaries Develop

The underlying mechanisms of PCOS are multifactorial, involving genetic predisposition, insulin resistance, and disordered gonadotropin secretion. Insulin resistance leads to compensatory hyperinsulinemia, which stimulates the ovaries to produce androgens. Elevated luteinizing hormone (LH), often driven by altered GnRH pulsatility, further amplifies ovarian theca cell androgen production. The excess androgens disrupt normal follicular development, causing follicles to arrest at the small antral stage. These follicles accumulate but never ovulate, giving the classic polycystic appearance on ultrasound. The resulting anovulation leads to low progesterone levels and unopposed estrogen stimulation, which in turn contributes to endometrial hyperplasia and irregular bleeding.

Obesity is a common comorbidity in PCOS, affecting 50% to 80% of women depending on the population. Adipose tissue itself contributes to estrogen production via aromatization of androgens, further worsening the hormonal imbalance. However, lean women can also develop PCOS, highlighting the importance of intrinsic ovarian and adrenal abnormalities.

Implications for Treatment: What Ultrasound Findings Mean for Management

Once a diagnosis of PCOS is established, identifying polycystic ovaries on ultrasound does not directly dictate a specific treatment plan, but it does help confirm the diagnosis and guide discussions about fertility and long-term risks. Women with PCOS who have a high follicle count often respond well to ovarian stimulation for ovulation induction, but they are also at increased risk of ovarian hyperstimulation syndrome (OHSS) when using fertility drugs. Therefore, ultrasound monitoring during treatment is essential.

Lifestyle Interventions

Lifestyle modification remains the first-line therapy for PCOS, especially in women with overweight or obesity. Weight loss of just 5% to 10% can improve insulin sensitivity, restore ovulation, and reduce androgen levels. Dietary approaches that focus on low-glycemic-index foods and regular aerobic exercise have shown particular benefit. In women with polycystic ovaries, lifestyle changes can lead to a reduction in follicle count and ovarian volume, though the ultrasound appearance may not fully normalize.

Pharmacologic Options

For women not seeking pregnancy, combined oral contraceptives are commonly used to regulate menstrual cycles, reduce androgen levels, and improve hirsutism and acne. The estrogen component suppresses LH and FSH, reducing ovarian androgen production, and the progestin component protects the endometrium. Metformin is another option, particularly for women with insulin resistance or impaired glucose tolerance. Metformin can improve ovulation rates and modestly lower androgen levels, but its effect on ultrasound morphology is variable. Antiandrogens such as spironolactone or finasteride can be added for hirsutism or hair loss, but they require reliable contraception due to potential teratogenicity.

Fertility Treatment

Women with PCOS who desire pregnancy often require ovulation induction. Letrozole (an aromatase inhibitor) is now considered first-line, as it has been shown to have higher live birth rates and lower rates of multiple gestation compared to clomiphene citrate. Gonadotropins are reserved for letrozole-resistant cases but require careful ultrasound monitoring to minimize OHSS risk. In women with polycystic ovaries, in-vitro fertilization (IVF) with a GnRH agonist trigger can further reduce OHSS incidence.

Long-Term Health Considerations

PCOS is associated with an increased risk of type 2 diabetes, cardiovascular disease, and endometrial cancer. The presence of polycystic ovaries does not independently raise these risks beyond the underlying metabolic and hormonal disturbances of the syndrome. Nevertheless, all women with PCOS should undergo regular screening for glucose intolerance, lipid disorders, and blood pressure monitoring. Endometrial surveillance is recommended for women with prolonged amenorrhea or abnormal uterine bleeding, especially if they are not using hormonal contraception or a progestin-releasing intrauterine device.

When Polycystic Ovaries Are Not PCOS

It is worth reiterating that polycystic ovarian morphology can occur in other conditions. Functional hypothalamic amenorrhea, hyperprolactinemia, and congenital adrenal hyperplasia can all produce irregular cycles and sometimes enlarged ovaries. Thyroid disorders and Cushing’s syndrome are also part of the differential. In addition, some women with normal ovulatory function and no hyperandrogenism simply have polycystic-appearing ovaries as a benign variant. Long-term follow-up in such women generally shows no increased risk of metabolic disease, though the data are limited.

Advances in Imaging and Future Directions

Machine learning algorithms are being developed to automatically count follicles and measure ovarian volume from ultrasound images, potentially reducing operator variability. 3D ultrasound and contrast-enhanced imaging are also being studied to assess ovarian stromal blood flow, which may correlate with androgen production. The recent use of anti-Müllerian hormone (AMH) as a surrogate marker for follicle count has gained traction. AMH, produced by granulosa cells of small antral follicles, is elevated in PCOS and correlates strongly with ultrasound findings. However, AMH alone cannot replace imaging because of inter-assay variability and lack of universal cutoffs.

Despite these advances, ultrasound remains the primary tool for assessing ovarian morphology. It is affordable, widely available, and noninvasive. Future guidelines may integrate AMH with ultrasound to improve diagnostic accuracy, especially in adolescents where transvaginal ultrasound may not be acceptable.

Conclusion

The connection between PCOS and polycystic ovaries on ultrasound is a cornerstone of modern diagnosis, but it must be understood within the broader clinical framework of hyperandrogenism and ovulatory dysfunction. Ultrasound provides essential evidence of ovarian morphology, but it is neither necessary nor sufficient for diagnosis on its own. A careful history, physical examination, and laboratory evaluation are required to confirm PCOS and to rule out other causes. Early and accurate diagnosis allows women to receive appropriate treatment for symptoms such as infertility, hirsutism, and menstrual irregularities, as well as preventive care for metabolic and cardiovascular complications. As imaging technology and biomarker research progress, the ability to identify and manage PCOS will only improve, offering better outcomes for the millions of women affected worldwide.

For further reading on diagnostic criteria and management, refer to the Endocrine Society Clinical Practice Guideline (link), the International PCOS Network Consensus (link), and the American College of Obstetricians and Gynecologists’ Practice Bulletin (link). Additional resources on lifestyle management can be found through the National Institutes of Health (link).